Colchicine’s Potential in Treating Metabolic Syndrome
Understanding Metabolic Syndrome
A recent study has investigated the use of colchicine, a medication typically prescribed for gout, in addressing metabolic syndrome, a serious diabetes-related complication. Approximately one-third of adults in the United States are affected by this condition, characterized by a combination of risk factors including high blood pressure, elevated blood sugar, excess body fat, and increased cholesterol and triglyceride levels. These factors collectively heighten the risk of heart disease, stroke, and type 2 diabetes.
Metabolic syndrome is closely linked to obesity and physical inactivity, but it is also associated with insulin resistance, which leads to elevated blood sugar levels. The likelihood of developing metabolic syndrome increases with age and is influenced by factors such as ethnicity, with Hispanic women in the U.S. being at the highest risk. Other contributing factors include obesity and diabetes. The most effective strategy for preventing metabolic syndrome involves adopting a healthy lifestyle characterized by regular exercise, a balanced diet, maintaining a healthy weight, and avoiding smoking.
Research Findings on Colchicine
Researchers from the National Institutes of Health published findings in the journal Diabetes, Endocrinology, and Metabolism, exploring colchicine’s potential to mitigate complications from metabolic syndrome. The study suggests that colchicine may play a role in preventing the formation of a protein complex that promotes inflammation associated with obesity. Previous studies have established a link between obesity and the onset of type 2 diabetes, prompting researchers to hypothesize that colchicine could reduce the risk of developing type 2 diabetes by combating inflammation.
In the study, 21 participants were randomly assigned to receive colchicine twice daily for three months, while 19 others were given a placebo. The primary objective was to evaluate insulin’s effectiveness in clearing glucose from the bloodstream. Additionally, researchers monitored changes in other metabolic parameters and inflammation markers.
While no significant difference in insulin resistance was observed between the two groups based on the frequently sampled, insulin-modified intravenous glucose tolerance test, the colchicine group demonstrated improvements in the Homeostatic Model Assessment of Insulin Resistance test. This test estimates the amount of insulin required to maintain normal fasting blood sugar levels. Participants receiving colchicine also exhibited lower levels of C-reactive protein and other indicators of inflammation.
Future Directions
The study’s authors concluded that further research with larger participant groups is essential to ascertain whether colchicine can effectively prevent the onset of type 2 diabetes in individuals with metabolic syndrome.
Written by Tatsiana Verstak, MS, BS
References
Demidowich, A.P. et al. Effects of colchicine in adults with metabolic syndrome: A pilot randomized controlled trial. Diabetes Obes Metab. 2019 Mar 14. doi: 10.1111/dom.13702.
Mayo Clinic. Metabolic Syndrome. Last updated March 14, 2019.